Short answer
Foghorn Therapeutics Inc. (FHTX) filed an 8-K current report with the SEC on October 1, 2026 reporting Item 2.05 (Costs Associated with Exit or Disposal Activities), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). FHD-909 Phase 1 will not advance to expansion after clinical-data review.
Foghorn Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.05 · Costs Associated with Exit or Disposal Activities
- FHD-909 Phase 1 will not advance to expansion after clinical-data review
- Lilly collaboration activities no longer anticipated, removing a partnered development path
- Workforce reduction of approximately 40%, with approximately 65 employees expected afterward
- Approximately $2.3 million in primarily severance and benefit charges, largely cash costs in Q4 2026
- Resources redirected toward EP300, CBP, immunology, inflammation, and proprietary platform programs
Item 7.01 · Regulation FD Disclosure
- Foghorn halted advancement of FHD-909 into the clinical trial expansion phase
- Strategic prioritization likely redirects resources toward other pipeline programs
- Exhibit 99.1 contains the company’s rationale and additional implications for investors
Item EX-99.1 · Exhibit EX-99.1
- Foghorn and Lilly will not advance FHD-909 after Phase 1 data failed to demonstrate sufficient efficacy
- Selective SMARCA2 degrader collaboration also ending, removing a partnered development path
- Resources shifting to wholly owned EP300, CBP, immunology, inflammation, and induced-proximity programs
- Approximately 40% workforce reduction intended to extend cash runway into the second half of 2029
- Strategic reset increases dependence on earlier-stage proprietary pipeline and execution of restructuring plans
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Foghorn Therapeutics Inc. 8-K filings
Get the next FHTX 8-K as it lands
Follow FHTX for push alerts, or ask the research agent what this filing means.